Add to ORKGcomparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitor
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't;Co...
Assessment of the impact of treatment on quality of life of patients with haemophilia A at different...
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't;Co...
The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEI...
Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant)...
On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and m...
The Pro-FEIBA study reported health-related quality of life (HRQoL) improved following 6-month of Fa...
Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated ...
Introduction: Up to 30% of patients with severe hemophilia A develop inhibitors to factor VIII (FVII...
52nd Annual Meeting of the American-Society-of-Hematology (ASH) -- DEC 04-07, 2010 -- Orlando, FLWOS...
The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEI...
In patients with severe haemophilia and inhibitors, regular factor VIII inhibitor bypassing activity...
and caregivers ’ perspectives on stability of factor VIII products for haemophilia A: a web-based st...
Summary: A growing number of publications have described the efficacy and safety of FEIBA as a first...
Geir E Tjønnfjord, Pål Andre HolmeMedical Department, Division of Hematology, Rikshospi...
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't;Co...
Assessment of the impact of treatment on quality of life of patients with haemophilia A at different...
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't;Co...
The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEI...
Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant)...
On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and m...
The Pro-FEIBA study reported health-related quality of life (HRQoL) improved following 6-month of Fa...
Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated ...
Introduction: Up to 30% of patients with severe hemophilia A develop inhibitors to factor VIII (FVII...
52nd Annual Meeting of the American-Society-of-Hematology (ASH) -- DEC 04-07, 2010 -- Orlando, FLWOS...
The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEI...
In patients with severe haemophilia and inhibitors, regular factor VIII inhibitor bypassing activity...
and caregivers ’ perspectives on stability of factor VIII products for haemophilia A: a web-based st...
Summary: A growing number of publications have described the efficacy and safety of FEIBA as a first...
Geir E Tjønnfjord, Pål Andre HolmeMedical Department, Division of Hematology, Rikshospi...
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't;Co...
Assessment of the impact of treatment on quality of life of patients with haemophilia A at different...
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't;Co...